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Abstract: Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth 
factor receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. 
In particular, the EXTREME study has indicated cetuximab as the only drug to improve 
survival when associated with cisplatin and 5-fluorouracil in patients with recurrent/metastatic 
disease. Furthermore, cetuximab, both alone and in combination with cisplatin, is active in 
patients with recurrent/metastatic disease who have failed prior platinum-based chemotherapy. 
Cetuximab, given in association with radiation therapy, is a treatment of choice in first-line 
therapy of patients with locally advanced inoperable disease. In the same setting, the role of 
induction chemotherapy has gained considerable interest over the last few years and a number 
of efforts are being pursued to optimally integrate induction chemotherapy with radiation 
therapy plus cetuximab. The combination of cetuximab and other targeted therapies is among 
the most promising new perspectives for patients with head and neck cancer.
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Introduction
Epithelial growth factor receptor (EGFR) is a member of the ErbB family of receptors 
which are composed of an extracellular ligand-binding domain, a hydrophobic 
transmembrane segment and an intracellular tyrosine kinases domain. After ligand 
binding, homodymeric or heterodymeric complexes are formed which activate in turn 
the tyrosine kinase domain and downstream effectors.1 Squamous cell carcinoma of 
the head and neck (SCCHN) represents a suitable tumor in which anti-EGFR therapy 
can be explored due to nearly ubiquitous EGFR expression and its prognostic value. 
EGFR plays a critical role in SCCHN growth, invasion, metastasis and angiogenesis,2 
and the mean EGFR levels in tumors are considerably higher than in normal tissue.3 
High EGFR copy number detected by fluorescence in situ hybridization (FISH) has 
been shown to be a poor prognostic indicator.4 A similar study,5 including 134 patients 
with diagnosis of SCCHN, demonstrated that aberrant EGFR copy numbers, evaluated 
by quantitative real-time polymerase chain reaction (Q RT-PCR), is also associated 
with a poor clinical outcome. In both of the studies, the increased EGFR copy number 
does not correlate with the protein expression levels. Recently, the role of any EGFR 
gene polymorphism was explored in several human epithelial neoplasms including 
SCCHN. These polymorphisms [nucleotidic substitution G/A in the 497 codon of the 
exon 13 (R497K); 216G/T substitution in SP1 region of the promoter; CA dinucleotidic 
repetitions in the intron 1] seem to increase gene EGFR expression and correlate 
with a poor prognosis.6OncoTargets and Therapy 2009:2 244
Perri et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Cetuximab
Cetuximab (Erbitux, C225) is a human-murine chimeric 
immunoglobulin G (IgG) monoclonal antibody that competi-
tively binds to the extracellular domain of EGFR and prevents 
binding by the natural EGFR ligands, the main of which are 
EGF and transforming growth factor-alpha (TGF-a). Among 
the entire panel of murine anti-EGFR antibodies, monoclonal 
antibody C225 was chosen for further clinical development 
for several reasons: it binds to the receptor with better affinity 
than the natural ligand; moreover, it also induces dimerization 
and downregulation of the EGF receptor which prevents 
further receptor binding and activation by the ligand. Potential 
clinical efficacy of cetuximab appears to involve multiple 
mechanisms, including inhibition of cell cycle progression, 
induction of apoptosis, inhibition of angiogenesis, inhibition of 
metastasis, and enhancement of the response to chemotherapy 
and radiation therapy.7
A phase I study of cetuximab was run by Baselga and 
colleagues who evaluated the pharmacokinetics and toxicity 
of cetuximab in 56 patients with advanced epithelial tumors 
over-expressing EGFR.7 Cetuximab was administered alone as 
a single dose in 14 patients, alone as weekly multiple doses in 
17 patients and as weekly multiple doses in combination with 
cisplatin in 22 patients. Doses in the range of 200 to 400 mg/m2 
were associated with complete saturation of  systemic clearance. 
Cetuximab infusion was well tolerated at the dose level 
tested and the most commonly reported toxicities were fever, 
asthenia, transaminase elevation, and skin toxicity.
Another similar phase Ib study8 has evaluated safety, 
pharmacokinetics and activity of cetuximab in combinat-
ion with cisplatin in patients with advanced SCCHN. 
Twelve patients who had high levels of EGFR expression and 
tumors easily accessible for repeated biopsies (pretherapy, 
24 hours after first C225 infusion, 24 hours before third 
C225 infusion) were entered at three different dose levels 
of C225 with a fixed dose of cisplatin. Both of the above 
studies indicated a loading dose of 400 mg/m2 with a weekly 
maintenance dose of 250 mg/m2 as the dose schedule to be 
recommended for further studies. Skin toxicity was the most 
common adverse event occurring in 70%–80% of patients, 
but it was rarely treatment limiting.
The aim of this review is to present and discuss the current and 
future role of cetuximab in the different subsets of SCCHN.
Recurrent/metastatic squamous cell 
carcinoma of the head and neck
Chemotherapy is the treatment of choice for recurrent/
metastatic disease in patients not suitable for further 
surgery or irradiation. Cisplatin is the most used drug in this 
setting and the combination of cisplatin and 5-fluorouracil 
(5FU) has represented the mainstay of first line treatment 
for the last twenty years. Several drugs have been used in 
combination with cisplatin and/or 5FU with the attempt 
to improve results.9
The taxanes have been shown to be active in SCCHN 
mainly in combination with cisplatin, but this activity has to 
be balanced against the mostly overlapping toxicity profile (in 
particular myelotoxicity and neurotoxicity). The combination 
of cisplatin and cetuximab has been studied in first line 
treatment of recurrent/metastatic disease. In particular, 
in the phase Ib study run by Shin and colleagues,8 treatment 
was feasible and hints of antitumor activity was observed. 
Burtness and colleagues10 carried out a phase III trial where 
117 patients with recurrent/metastatic SCCHN were randomly 
assigned to receive cisplatin 100 mg/m2 every four weeks 
with weekly cetuximab or placebo. Progression-free survival 
(PFS) was not statistically different between the two treatment 
groups. In particular, median PFS was 4.2 months for patients 
treated with cisplatin plus cetuximab and 2.7 months for 
patients treated with cisplatin plus placebo (p = 0.09). 
Median overall survival (OS) was also not statistically 
different between the two groups; (9.2 and 8.0 months, 
p = 0.21). Response rate was 26% and 10% in the two arms, 
respectively (p = 0.03). Patients treated with cisplatin and 
cetuximab experienced more frequently grade 3/4 toxicity 
which was mostly due to cisplatin. As expected, skin toxicity 
was more frequent in the experimental arm (37.7%) than in 
the control arm (23%) (p  0.001). The issue of combining 
cetuximab with platinum (cis or carbo) and 5FU in recurrent 
metastatic disease was first addressed by Bourhis and 
colleagues in 53 patients. A substantially higher incidence of 
serious adverse events were observed in the cisplatin group 
(67%) than in the carboplatin group (32%); overall response 
rate was 36% and disease control rate was 74%, with no 
substantial difference between cisplatin and carboplatin. 
In the entire population time to tumor progression (TTP) 
was 155 days and median survival was 297 days.11 This 
study paved the way to phase III evaluation. The EXTREME 
study, a phase III study comparing cisplatin-5FU with or 
without cetuximab, has provided evidence of statistically 
significant advantage in terms of locoregional control and 
overall survival for the experimental arm. In particular, 
median PFS was 5.6 months in the experimental arm and 
3.3 months in the control arm (p  0.001). Overall survival 
was 10.1 months vs 7.4 months in the experimental and in 
the control arm, respectively (p = 0.04). Overall response OncoTargets and Therapy 2009:2 245
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rate was 36% vs 20% in the experimental and control arm, 
respectively (p  0.01). As for toxicity, no differences in the 
grade 3/4 adverse events were recorded in the two arms.12
The prognosis for patients progressing after cisplatin con-
taining regimen is very poor, with less than 5% response rate. 
On this basis, cetuximab has been tested in this setting.
Herbst and colleagues13 conducted a phase II trial 
in 131 patients who had obtained a stable disease (SD) 
or a progressive disease (PD) after a platinum-based 
chemotherapy. The combination of cetuximab and cisplatin 
was given to these patients who were divided into three 
subgroups: patients that had obtained a SD (SD cohort), 
patients that had obtained a PD after two cycles of CT (PD1 
cohort) and patients that had obtained a PD after three or 
more cycles of CT (PD2 cohort). The objective response rate 
was 18% for the SD cohort, 20% for the PD1 cohort and 6% 
for the PD2 cohort. The median duration of response was 
7.4 months for the SD cohort, 4.2 for the PD1 cohort and 4.1 
for the PD2 cohort. Median overall survival for SD cohort 
was 11.7 months. The most common grade 3 and 4 cisplatin 
toxicities were myelosuppression and nephrotoxicity but 
there was no indication that cisplatin-based toxicity was 
exacerbated in combination with cetuximab, which induced 
the appearance of skin rash in 70% of patients.
Baselga and colleagues14 conducted a multicenter 
phase II trial of the combination of cetuximab and platinum 
therapy in patients with platinum-refractory SCCHN. Partial 
response (PR) and disease control rate was 10% and 53%, 
respectively. Median time to progression and overall survival 
were 72 and 150 days, respectively.
In patients who achieved a PR, the median TTP was 
185 days and OS was 272 days. In addition, the median 
TTP and median OS were longer in patients receiving the 
three-week cycle compared with patients receiving the four-
week-cycle. Skin reactions and acne-like rash occurred in 80% 
of patients, but only 3% of patients experienced a grade 3–4 
cutaneous rash. This study demonstrated that the combination 
of cisplatin and cetuximab has a good activity in this popula-
tion of platinum-refractory SCCHN patients and the results 
were particularly encouraging in view of the fact that more 
than half of the patients had received more than two cycles of 
platinum-based chemotherapy as first-line therapy.
The results of these two trials suggested that cetuximab 
given in association with cisplatin might have a role in 
reversing platinum resistance.
Moreover, cetuximab is effective also when given alone in 
patients with platinum-refractory SCCHN. In fact, Vermorken 
and colleagues15 tested single-agent cetuximab in a group 
of 103 patients with SCCHN that had progressed after a 
platinum regimen. No patients achieved complete response, 
13% of patients achieved a partial response while the dis-
ease control rate was 46%. The median TTP was 70 days 
and OS was 178 days. Progressive patients were switched 
to the cetuximab/cisplatin combination. In these patients, 
no objective responses were recorded but 27% of patients 
had a stable disease.
Cetuximab has been associated also to taxanes in patients 
with recurrent/metastatic disease. The combination of weekly 
docetaxel and standard cetuximab induced a 20% partial 
response rate and a 47% disease control rate in 45 patients.16 
Paclitaxel was also evaluated in combination with platinum 
and cetuximab and a significant tumor response rate (56%) 
was observed.17
Locally advanced inoperable 
squamous cell carcinoma
Radiation therapy has been the treatment of choice in this 
subset of patients for several decades.9 However, clinical 
evidences now exist in favor of combined treatment approach, 
which includes chemotherapy and radiation therapy. 
In fact, several randomized trials have shown that adding 
concurrent chemotherapy to radiation significantly increases 
locoregional control. Furthermore, a recent meta-analysis 
reported an 8% increase in five-year survival with the 
combined approach.18 The common standard for chemotherapy 
in combination with radiation is cisplatin given at the dose 
of 100 mg/m2. However, the combined administration of 
chemo and radiation therapy is significantly more toxic 
than radiotherapy alone, both in terms of acute toxicities 
(mucositis, dermatitis, leucopenia, emesis) and delayed 
toxicities (feeding tube dependence, pharyngeal and laryngeal 
dysfunction). Furthermore, the combined administration 
of chemo- and radiotherapy compromises postoperative 
adherence to further treatments19 and is associated with more 
frequent and longer treatment interruptions than radiation 
therapy; in turn, delays in radiation therapy delivery can 
adversely affect patient outcomes.19
It is well known that tumor cell repopulation during 
treatment is implicated as a cause of treatment failure 
after primary radiotherapy.20 However, several studies 
have reported that repopulation of epithelial tumor cells 
after exposure to radiation is related to the activation and 
expression of EGFR.21–22 These findings suggest that EGFR 
blockade may be important in reducing tumor cell repopu-
lation after radiotherapy and this strategy may improve 
tumor control.OncoTargets and Therapy 2009:2 246
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Several preclinical studies have investigated the effect 
of combined C225/radiation treatment in cell lines derived 
from human SCCHN.23 Such combined treatment resulted 
in a strong decrement in cellular proliferation. Saleh 
and colleagues demonstrated that, in cell lines derived by 
human SCCHN, addition of C225 to radiation treatment was 
able to inhibit cellular proliferation by approximately 35% 
for the lowest EGFR expressing cell lines and by 70% for 
the highest expressing cell lines.24
A phase I trial of cetuximab and radiation therapy was 
carried out at the University of Alabama.25 Thirteen of 
15 patients achieved a complete response whereas a partial 
response was seen in the remaining two patients. Median 
duration of response was 28 months and toxicity data 
highlighted the safety of this approach without the need of 
dose modification. Recently Bonner and colleagues published 
a phase III trial comparing radiotherapy alone with the com-
bination of cetuximab and radiotherapy in locally advanced 
inoperable SCCHN (424 patients). The experimental arm 
showed a statistically significant superiority in locoregional 
control and overall survival; in particular, duration of locore-
gional control was 24.4 months with combined treatment and 
14.9 months (p = 0.005) in the control arm. Median survival 
time was 49 months in the experimental arm and 29.3 months 
in the control arm (p = 0.03); median PFS was 17.1 months 
and 12.4 months in the two arms respectively (p = 0.006). 
Cetuximab did not worsen the main toxicities associated to 
radiotherapy.26 Quality of life (QoL) in these patients was 
assessed by Curran and colleagues27 in a follow-up analysis in 
which QoL was assessed using two different questionnaires, 
the European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30 which evaluates functioning and 
symptoms common to most cancer patients, and the QLQ 
HeN35 which evaluates symptoms specifically associated 
with head and neck cancer and its treatment. Compliance with 
completion of QoL questionnaires was high in both arms and, 
most importantly, there was no significant difference in QoL 
scores between the two treatment arms.
Cetuximab is now approved for use in combination with 
exclusive radiation treatment in patients with diagnosis of 
locally advanced inoperable SCCHN.
The following logical step was to combine cetuximab with 
radiation therapy and chemotherapy. Pfister and colleagues28 
conducted a phase II study of a combined regimen of weekly 
cetuximab administered with conventional schedule and 
associated to standard cisplatin and radiotherapy. A total of 
22 patients were enrolled in the study. Mucositis, skin rash, 
nausea, and vomiting were the main observed toxicities. 
This study was closed early because of five serious adverse 
events including two deaths, one myocardial infarction, 
one bacteremia, and one atrial fibrillation. Three complete 
responses and 13 partial responses were observed in the 
16 assessable patients. Three-year PFS and overall survival 
rate were 56% and 76%, respectively. However, this regimen 
was not recommended for further evaluation due to heavy 
toxicity. Similar results were reported by Merlano and 
colleagues.29 The response rate was 100%, but impressively 
high toxicity was reported with particular regard to skin 
toxicity. Kuhnt and colleagues30 evaluated the combination 
of concomitant hyperfractionated accelerated radiotherapy 
(HART) with cisplatin and cetuximab. Fourteen patients 
were treated and a response rate of 91% was achieved. The 
treatment was well tolerated and weekly cisplatin at the 
dose of 40 mg/mg2 was recommended in combination with 
cetuximab plus HART.
The role of induction chemotherapy in patients with 
locally advanced inoperable disease has gained considerable 
interest in the last two years with the publication of 
two phase III trials of docetaxel, cisplatin, 5FU vs cisplatin, 
5FU. The first study was carried out by the EORTC.31 
Patients were randomized to receive four cycles of either 
TPF (docetaxel and cisplatin 75 mg/m2 on day one, 5FU 
750 mg/m2/day, for five days of continuous infusion) 
or standard PF (cisplatin 100 mg/m2 on day one, 5FU 
1000 mg/m2 daily for five days of infusion). Radiation 
therapy was subsequently administered. PFS was higher 
in the experimental arm (11.0 vs 8.2 months, p = 0.007). 
Median overall survival was 18.8 months vs 14.5 months 
(hazard ratio = 0.73). Response rate was also significantly 
higher in the experimental arm (68% vs 54%, p = 0.006). 
Complete response rate was 9% vs 6% , p = n.s). Although 
neutropenia, as expected, was more frequent in the TPF arm, 
the toxic death rate was 2.3% in the TPF arm and 5.3% 
in the PF arm. Quality of life was also better in patients 
in the TPF arm (p = 0.01). The second phase III study 
was carried out by Posner and colleagues.32 The treatment 
plan was very similar to the other study and three cycles 
of TPF (docetaxel 75 mg/m2, cisplatin 100 mg/m2 on day 
one, 5FU 1000 mg/m2 daily for four days of continuous 
infusion) were compared with three cycles of standard PF. 
Radiation therapy was administered for seven weeks and 
was combined with weekly carboplatin therapy. Overall 
survival was higher in the TPF group (71 vs 30 months, 
respectively; p = 0.006); locoregional control was also better 
in the TPF group (p = 0.04). Overall response rate favored 
the experimental arm (72% vs 64%), but the difference was OncoTargets and Therapy 2009:2 247
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not significant. These two studies have represented a major 
breakthrough and have provided evidence that induction 
chemotherapy followed by irradiation can represent the 
best option in many cases. The next step is how to optimally 
integrate induction chemotherapy with cetuximab therapy 
in order to further improve treatment outcome by giving 
patients all the most effective therapeutic options in first 
line of treatment.
Kies and colleagues33 reported a study of induction 
chemotherapy with weekly paclitaxel, carboplatin and 
cetuximab in patients with inoperable disease. Complete 
response rate, which was the main endpoint of the study, 
was observed in 83% of 47 evaluable patients at the primary 
site and in 27% at the nodal site. Hematologic and skin 
toxicities were the only observed grade 3/4 adverse events. 
The Eastern Cooperative Oncology Group (ECOG) has 
evaluated the combination of cetuximab, paclitaxel and 
carboplatin followed by cetuximab, carboplatin and radiation 
therapy in patients with locally advanced SCCHN. A high 
rate of complete pathological responses at the tumor site 
was observed; in particular 40/63 patients were clinical 
responders at week 8 after induction therapy. Among these, 
63% of patients had complete pathological response at week 
14 after chemoradiotherapy. Grade 4 neutropenia was the 
main adverse event being observed in 14% of patients.34 
Tishler and colleagues have recently presented a phase I study 
of cetuximab added to TPF induction chemotherapy. This 
was conceived as phase I study because of 5FU escalation 
in association with standard doses of docetaxel, platinum 
and cetuximab. Preliminary results showed 11 partial 
responses out of 15 evaluable patients. 850 mg/m2 was the 
5FU selected dose.35 A retrospective analysis of addition 
of cetuximab to induction TPF has been performed by 
Kuperman and colleagues. Standard doses of the four drugs 
were used; overall response rate was 71% in 21 enrolled 
patients; the toxicity profile was foreseeable and mild.36 
Argiris and colleagues have recently reported a phase II 
study of neoadjuvant docetaxel, cisplatin and cetuximab 
followed by concurrent radiation, cisplatin and cetuximab 
in locally advanced SCCHN. The overall response rate to 
induction chemotherapy was 86% in 37 evaluable patients. 
After the combined chemoradiotherapy the overall response 
rate was 100%. Hematologic and skin toxicities were the 
most relevant adverse events also in this study.37 Langer and 
colleagues have presented preliminary data of the ECOG 
3303 study in which concurrent radiotherapy, cisplatin and 
cetuximab was given to 61 patients. The overall response 
rate was only 48% in this study. Moreover, a number of 
relevant adverse events including a death from neutropenic 
fever were observed.38 Bonnin and colleagues administered 
induction TPF (docetaxel 75 mg/m2 on day 1, cisplatin 
75 mg/m2 on day 1 and fluorouracil 750 mg/m2 on day 
1–5, to be repeated every 21 days for 3 cycles) followed by 
concurrent chemoradiotherapy (cisplatin or cetuximab) in 
123 patients with unresectable SCCHN. The overall response 
rate was 96% after induction chemotherapy, but subsequent 
chemoradiotherapy turned out to be very toxic showing a 
64% of grade 3–4 toxicity.39
Taken as a whole, these data show that appropriate 
integration of cetuximab, radiotherapy and induction chemo-
therapy have the possibility to improve treatment outcome in 
the near future. The results of completed and ongoing studies 
of cetuximab in the different subsets of patients with SCCHN 
are summarized in Tables 1 and 2.
New perspectives
The importance of cetuximab in the therapeutical armamen-
tarium against SCCHN has considerably increased. The 
concomitant use of chemoradiotherapy and cetuximab has 
not matched the expectation, but its role is being revisited.
The Radiation Therapy Oncology Group (RTOG) is 
running a phase III randomized trial of chemoradiotherapy 
vs chemoradiotherapy plus cetuximab in patients with 
stage III/IVa squamous cell carcinoma of the oropharynx, 
hypopharynx or larynx. After stratification by site of primary, 
performance status, regional nodes, patients are to receive 
cisplatin conventional dose plus accelerated radiotherapy and 
concomitant boost with or without the addition of cetuximab 
at the common dose schedule.
Evaluation of cetuximab in the adjuvant setting is a fur-
ther way to explore the potential of this compound. RTOG 
is running a randomized trial in locally advanced resected 
patients judged at high risk of relapse. Patients are random-
ized to receive radiation therapy plus cetuximab plus weekly 
cisplatin in the arm A and radiotherapy plus cetuximab plus 
weekly docetaxel in the arm B. On the other hand, another 
phase III trial is being conducted in patients with intermediate 
risk of relapse. Patients are randomized to receive either 
radiation therapy alone or cetuximab plus radiation therapy. 
Preliminary results are not yet available for each of the 
two studies; however, they are eagerly awaited since they 
are going to provide information on the possible usefulness 
of cetuximab also in the adjuvant setting.
An appealing new strategy involves the combination 
of different EGFR-targeted therapies, ie, the combined 
administration of a monoclonal antibody and a tyrosine OncoTargets and Therapy 2009:2 248
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kinase inhibitor. A sound preclinical rationale for this 
approach does exist. In fact, while monoclonal antibodies 
require an intact EGFR ligand binding domain, tyrosine 
kinase inhibitors are also active against mutated forms of 
the EGFR. Furthermore, monoclonal antibodies can also 
elicit antibody-dependent cellular cytotoxicity. Matar and 
colleagues40 have evaluated the combination of gefitinib 
and cetuximab in a panel of human cancer cell lines and in 
an EGFR-dependent human tumor xenograft model (A431). 
The combined treatment with the two agents resulted in a 
synergistic effect on cell proliferation, a greater inhibition 
of EGFR-depending signal and induction of apoptosis. 
In in vivo experiments single agent gefitinib or cetuximab 
induced transient complete remission only at the highest 
doses, while suboptimal doses of both drugs given in 
combination induced complete and permanent regression 
of large tumors with a greater inhibition of EGFR, MAP-K, 
and AKT phosphorylation. The evaluation of cDNA arrays 
showed that while 59 genes were coregulated by the two 
agents, 45 genes were differentially regulated, strengthening 
the rationale of the combined administration. Huang and 
colleagues41 evaluated the potency of EGFR inhibition in 
a variety of human cancer cell lines after treatment with 
combination of cetuximab and either gefitinib or erlotinib. 
The combination enhanced growth inhibition over that 
observed with either single agent alone. In vivo data 
confirmed that higher tumor regression and growth delays 
were observed in mice treated with the combination. Taken 
as a whole, these studies may pave the way to clinical 
evaluation of combinations of EGFR-targeted agents.
Simultaneous targeting of multiple pathways is an 
attractive strategy of cancer treatment. In particular, the 
combined use of drugs targeting EGFR and vascular 
endothelial growth factor (VEGF) pathways is an appealing 
approach since angiogenesis has been associated with tumor 
progression and worse outcomes. Furthermore VEGF is often 
upregulated in tumors resistant to anti-EGFR compounds. 
Most of the clinical studies which have been run with the 
combination of anti-EGFR and anti-VEGF compounds have 
involved erlotinib and bevacizumab. However, early results 
of a clinical trial involving the combination of cetuximab 
and bevacizumab have been presented in patients with recur-
rent/metastatic SCCHN that had progressed after a prior line 
of chemotherapy.42 This combination showed a good clinical 
activity with a disease control rate of 80%. Further trials are 
needed to confirm this encouraging result.
Table1 Completed clinical trials with cetuximab in SCCHN
Trial N. patients Phase Design Endpoints Results Setting
Burtness et al10 117 iii CDDP-cetuximaba 
vs 
CDDP
OS 
PFS 
Orr
Not significant 
Not significant 
Significant (p = 0.03)
First-line  
recurrent/metastatic
Bourhis et al11 53 ii CDDP-5FU-cetuximab Orr 36% First-line 
recurrent/metastatic
vermorken et al12 442 iii CDDP-5FU-cetuximaba 
vs 
CDDP-5FU
OS 
PFS 
Orr
Significant (p = 0.04) 
Significant (p = 0.001) 
Significant (p = 0.001)
First-line  
recurrent/metastatic
Herbst et al13 132 ii CDDP-cetuximab Orr 12,8% Second-line 
(Platinum-refractory) 
recurrent/metastatic
Baselga et al14 96 ii CDDP-cetuximab Orr 10% Second-line  
(Platinum-refractory) 
recurrent/metastatic
vermorken et al15 96 ii Cetuximab Orr 13% Second-line 
(Platinum-refractory) 
recurrent/metastatic
Bonner et al26 424 iii radiotherapy-cetuximaba  
vs  
radiotherapy
PFS 
OS 
Orr
Significant (p = 0.005) 
Significant (p = 0.003) 
Significant (p = 0.02)
Locally advanced disease
Pfister et al28 21 ii radiotherapy-CDDP  
+ cetuximaba 
vs 
radiotherapy-CDDP
Orr 94% Locally advanced disease
Notes: aexperimental arm. 
Abbreviations: OS, overall survival; PFS, progression free survival; Orr, overall response rate.OncoTargets and Therapy 2009:2 249
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Finally, the relationship between the RAS gene family, 
particularly K-ras, and tumorigenesis has generated 
considerable interest. In particular, the occurrence of K-ras 
mutation has been associated with the effectiveness of 
cetuximab and other drugs interfering with EGFR signaling 
in advanced colorectal cancer.43 As for head and neck cancer, 
overexpression and mutation of members of the RAS gene 
family have been observed more rarely,44–45 but clinical trials 
in this setting are well worth undertaking.
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